Widespread cervical screening in developed countries has led to a dramatic decline in the incidence of cervical squamous cell carcinoma; however, the rate of endocervical adenocarcinomas remains the same or is on the rise ([@bib28]; [@bib2]). The false negative rate in the cytological screening for cervical adenocarcinomas overall is higher than that for squamous lesions ([@bib19]). The overlapping cytological features between reactive and neoplastic glandular cells may have an important role in the underdiagnosis of glandular neoplasia, and this is particularly true in the diagnosis of early or well-differentiated adenocarcinoma, such as minimal deviation adenocarcinoma (MDA). The cervical adenocarcinomas encompass a heterogeneous group of tumours, including mucinous and non-mucinous types. The mucinous type includes the prototypical endocervical adenocarcinoma of usual type and other subtypes, such as intestinal, villoglandular and MDA. The non-mucinous tumours include endometrioid, clear-cell, serous and mesonephric types. Recently, a subtype of mucinous adenocarcinoma expressing gastric phenotype (GA) has also been described. To date, this type of adenocarcinoma has been primarily identified in the Japanese population and the term 'gastric-type endocervical adenocarcinoma\' has been used in the literature ([@bib9]; [@bib11]; [@bib26]). The tumour shows voluminous amounts of gastric-type mucin within the cytoplasm, giving a pale eosinophilic appearance of neoplastic cells. The cytological atypia can be mild to severe. It has been postulated that MDA is an extremely well-differentiated form of the broader category of GA ([@bib5]; [@bib21]). Minimal deviation adenocarcinoma of the cervix is a neoplasm distinguished by its deceptively bland histological features. Although the lesion only accounts for 1 to 3% of all endocervical adenocarcinomas, the prognosis of the advanced-stage disease is poor. In fact, delayed diagnosis occurs in most of the cases ([@bib3]). In 1999, Nucci and co-workers described a new pseudoneoplastic glandular lesion of the cervix, termed lobular endocervical glandular hyperplasia (LEGH) and considered this as a hyperplastic glandular lesion, sharing similar clinical and histological features with MDA. The importance of the separation between LEGH and MDA has been emphasised in the past. However, in recent years it has been speculated that LEGH may represent the precursor of GA, incorporating MDA as its well-differentiated form based on the following observations: (1) up to 19% of cases of LEGH showed coexisting GA ([@bib22]); (2) both LEGH and GA share a similar immunophenotype of gastric pyloric glands ([@bib20], [@bib21]); and (3) it has been postulated that MDA with gastric phenotype may represent an extremely well-differentiated form of GA. Lastly, one recent study has shown that copy number gains of chromosome 3q and loss of 1p in 3 of 14 (21%) LEGHs were also common to MDA and mucinous adenocarcinoma ([@bib7]). This observation is consistent with a possible molecular--genetic link between LEGH and GA/MDA. Therefore, it appears that separating LEGHs from other mimics of benign cervical glandular lesions is as important as correctly diagnosing GAs/MDAs.

Infection with oncogenic high-risk human papillomavirus (H-HPV) type(s) is widely accepted to be an important aetiological factor for cervical cancer ([@bib35]; [@bib1]). High-risk human papillomavirus has been detected in 97--99% of cervical cancers ([@bib31]; [@bib15]) and 83--100% of adenocarcinomas and their precursor glandular lesions ([@bib27]; [@bib15]). *P16*^*INK*^4^*a*^ (hereafter termed p16) is a tumour suppressor gene that has a central role in the regulation of the cell cycle. It has been shown that strong p16 expression in cervical carcinomas is associated with H-HPV infection. Thus, p16 has been commonly accepted as a surrogate biomarker for diagnosing cervical dysplasia/neoplasia associated with H-HPV infection ([@bib8]; [@bib23]). However, in recent years, certain subsets of cervical adenocarcinomas have been identified, namely MDA and mucinous GA, clear-cell carcinoma and mesonephric carcinoma that are not associated with H-HPV infection ([@bib27]; [@bib11]; [@bib26]).

In the 1990s, the antigen MN was identified ([@bib34]). MN is a glycoprotein, and was found to be a member of the carbonic anhydrase (CA) gene family, designated CA-IX ([@bib25]). Carbonic anhydrase-IX is a biomarker of several human tumours, including carcinomas of the cervix and kidney ([@bib12], [@bib14]). Carbonic anhydrase-IX expression in cancerous tissues, and its absence in normal counterparts, has led to the speculation that it has a role in carcinogenesis ([@bib32]; [@bib6]). Its expression is controlled by the transcription factor, hypoxia-inducible factor-1, and is upregulated in hypoxic regions of tumour tissues ([@bib32]; [@bib6]; [@bib29]).

In a survey of benign and neoplastic cervical tissues and PSs, it was observed that high levels of CA-IX were expressed by virtually all atypical glandular cells associated with adenocarcinoma *in situ* (AIS) and adenocarcinoma, but in the benign cervix CA-IX protein was either undetected or present in low levels, restricted to a few endocervical glandular cells and reserve cells. This suggested that high levels of CA-IX expression in cervical glandular cells may serve as a useful biomarker for diagnosing conventional glandular lesions (CGLs) of the cervix, including AIS and adenocarcinoma ([@bib12], [@bib15]; [@bib13], [@bib16]). However, CA-IX expression in special subtypes of cervical lesions, such as LEGH and GA/MDA, has not been reported.

In 1998, the Gynaecologic Oncology Group (GOG), an international multi-institutional clinical trials group supported by the US National Cancer Institute, conducted a study of women with a cytological diagnosis of atypical glandular cells of undetermined significance (AGC). A total of 25 Institutions in the United States ([@bib15]) and 11 institutions in Japan participated in the trial ([@bib17]). In the Japanese cohort, H-HPV had a sensitivity of 53% in CGLs and an overall specificity of 86%, whereas CA-IX had a sensitivity of 100% in CGLs and an overall specificity of 50% ([@bib17]). In a retrospective histological review of all cases retrieved from the Japanese cohorts, there were 13 cases of LEGH identified. Among these LEGH cases, three coexisted with AIS and three with GA. All of these three GAs were well differentiated with coexisting morphological spectrum of MDA. Here we report the results of H-HPV testing, using polymerase chain reaction (PCR), and p16 and CA-IX expression, using immunohistochemical staining, in the Japanese cases of LEGH and LEGH with coexisting AIS or GA. The objective of this study was to determine the degree of association between H-HPV infection, p16 and CA-IX expression, in LEGH, and in cases of LEGH with coexisting AIS and GA, and to ascertain their relative diagnostic utility. For comparative purposes, we included cases of CGLs from the same Japanese cohort.

Materials and methods
=====================

The criteria of AGC diagnosis for patient enrolment were based on the 1991 TBS classification ([@bib10]) and conventional PSs were used. The protocol used in this study was approved by the National Cancer Institute, Division of Cancer Prevention and the GOG Human Research Committee, and annually by the Institutional Review Board (IRB) at each of the participating institutions.

Patient selection and tissue samples
------------------------------------

Women over the age of 18 years, with a referring diagnosis of AGC and who were expected, on a clinical basis, to undergo complete histological evaluation of the cervical transformation zone, either with LEEP and/or cold knife cone or hysterectomy within 6 months of the initial cytological diagnosis, were enrolled in the study. Before enrollment all patients signed an informed consent form. Sample collection, patient eligibility, clinical management and histological evaluation have been described elsewhere ([@bib15], [@bib17]). Briefly, all H&E-stained histological slides of the most abnormal lesions from each diagnostic procedure were reviewed centrally by the teams of two gynaecological pathologists from the GOG Pathology Committee who reached a consensus diagnosis. The diagnosis of each case was entered to the Statistical Data Base. Retrospective review of the histology of all H-HPV tested cases enrolled in the Japanese study population was conducted by one of the authors (SYL). The diagnosis of LEGH and LEGH with atypical features was established based on the criteria proposed by [@bib24] and [@bib21]. Briefly, LEGH without atypia was defined as follows: (1) proliferation of small glands in a lobular manner; (2) abundant intracytoplasmic mucin giving a pale eosinophic appearance of glandular cells; (3) basally located round nuclei without anaplasia; and (4) absence of distinct evidence of destructive stroma ([Figure 1A](#fig1){ref-type="fig"}). Lobular endocervical glandular hyperplasia with atypical features was defined as follows: (1) nuclear enlargement, with irregularity and conspicuous nucleoli; (2) loss of polarity and papillary growth; and (3) the presence mitotic figures and apoptotic bodies and/or nuclear debris in the lumen ([Figures 1C, D](#fig1){ref-type="fig"} and 3A, D). The novel criteria outlined by [@bib9] were used to define the diagnosis of GA. Those criteria are: (1) clear or pale eosinophilic cytoplasm; (2) voluminous cytoplasm; and (3) distinct cell borders ([Figures 1F](#fig1){ref-type="fig"} and [2D](#fig2){ref-type="fig"}). For conventional endocervical adenocarcinoma, AIS, the World Health Organisation (WHO) classification ([@bib30]) was used. To be consistent with our previous reports ([@bib15], [@bib17]), in this study we use the term CGL to apply to conventional endocervical adenocarcinoma and AIS without coexisting LEGH, and GA to apply to cases with the morphological spectrum of MDA but with gastric phenotype, associated with LEGH. There were 84 cases with known H-HPV data enrolled in the Japanese cohort, and among these, 12 CGLs, 7 LEGHs and 6 LEGHs with coexisting AIS or GA were identified. All of the cases of CGL, LEGH, LEGH with AIS or GA were independently reviewed by the second gynaecological pathologist (WHR) and consensus was reached in all cases. All 84 cases with known H-HPV data were screened for p16 and CA-IX expression in the tissue sections of the cervix and CA-IX expression in the PSs. Among these, 27 cases with benign cervix were included in the study to serve as the negative control group.

Immunohistochemistry
--------------------

### Detection of CA-IX in a conventional study PS

Immunodetection of CA-IX was performed on conventional study PSs using the anti CA-IX mouse monoclonal antibody, M75, as described previously ([@bib12]). Specific immunostaining was defined by the presence of a brown reaction product along the plasma membrane under × 40 magnification. Faint staining of the cytoplasm was considered negative. Immunostaining was scored as positive or negative as described previously ([@bib13]; [@bib17]). Briefly, the positive reaction was defined as when any immunoreactivity was identified in atypical cells or strong dark brown membranous positivity was observed in the normal looking endocervical cells. No immunoreactivity or faint staining was considered as negative.

### Detection of CA-IX and p16 in tissue sections

Carbonic anhydrase-IX and p16 immunostaining was performed on 5-*μ*m-thick sections of formalin-fixed paraffin-embedded tissues, using CA-IX and p16 antibodies (clone G175-405; BD Pharmingen, Erembodegem-Aalst, Belgium). The Ventana amplification ultraview DAB detection kit in a Ventana BenchMark XT processor (Ventnana, Tucson, AZ, USA) was used for detecting CA-IX and p16 protein expression. The appropriate antigen retrieval methodology was used according to the manufacturer\'s recommendation. The dilutions of antibodies used were as follows: CA-IX (1 : 5000) and p16 (1 : 25). The extent and the intensity of immunostaining were evaluated independently by two pathologists (SYL and WHR) and consensus was reached in all cases. The extent was recorded semiquantitatively as the percentage of the cells that showed positive staining, as follows: negative (\<5% of the cells), focal (5--49% of the cells) and diffuse (⩾50% of the cells). The intensity was graded as negative (0), weak (1+) and moderate to strong (2+ to 3+). For p16, both cytoplasmic and/or nuclear staining was recorded. Faint cytoplasmic staining (+/−) was considered as a nonspecific reaction.

### HPV genotyping

The detection method employed a modified E6/E7-specific consensus PCR, using mixed primers (pU-1M, pU-1M-L/pU-2R and pU-2R-N). The PCR method used was a minor modification of published procedures ([@bib4]; [@bib33]), where modification of the primer sequences made it possible to amplify 13 H-HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 58, 67, 68 and 70). The PCR-based procedure was performed by the Takara Bio Corporation (Otsu, Shiga, Japan). The sequence of the PCR reactions was 94 ^o^C for 30 s, 55 °C for 60 s and 72 ^o^C for 60 s, and each cycle was repeated 35 times. Polymerase chain reaction product sizes ranged from 231 to 271 base pairs and represent the E6 and E7 regions of the H-HPV types. Genotyping of H-HPV DNA was performed according to the restriction fragment length polymorphism method described by [@bib18]. In situations where genotyping was not detected by restriction enzyme analysis, it was determined by direct sequencing of the amplified products.

Results
=======

There were 84 cases with known H-HPV data enrolled in the Japanese cohort, and among these, 13 LEGHs were identified. Among these 13 cases of LEGH, 6 had coexisting mucinous adenocarcinoma: 3 were *in situ* and 3 were invasive. All three invasive adenocarcinomas were extremely well differentiated and exhibited histological features of mucinous GA as described by [@bib9]. For comparative purposes, 12 cases of H-HPV-positive CGLs, including AIS (*n*=8) and adenocarcinoma (*n*=4), and 27 cases with benign cervix identified in the Japanese cohort were also included in the study. The 27 benign cases were used as the negative control group. The ages of the patients ranged from 36 to 80 (median: 55 years) in all cases of LEGH with or without AIS or GA, and from 32 to 56 (median: 45 years) in those patients with CGLs. Characteristic histological features of LEGH, described as well-demarcated proliferation of glands with a lobular architecture, with the glands lined by tall, mucin-rich columnar cells with a basal arrangement of nuclei, were seen in all cases of LEGH ([Figure 1A](#fig1){ref-type="fig"}). Out of 13 LEGHs, 12 exhibited variable degrees of atypical features either focal or diffuse, including nuclear enlargement, conspicuous nucleoli, loss of polarity, papillary growth and mitosis/apoptosis ([Figures 1C, D](#fig1){ref-type="fig"} and [3A, D](#fig3){ref-type="fig"}). Among these, three had coexisting AIS ([Figure 1E](#fig1){ref-type="fig"}) and three had coexisting GA ([Figures 1F and 2D](#fig1){ref-type="fig"}).

H-HPV infection
---------------

All cases of CGL, LEGH and LEGH with AIS or GA/MDA were tested for H-HPV infection. The results are summarised in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}. High-risk human papillomavirus DNA was detected in 83% (10 out of 12) of the CGLs ([Table 1](#tbl1){ref-type="table"}). All but one contained a single genotype: 7 (3 AIS, 4 adenocarcinomas) were type 18; 2 AIS were type 16; and 1 AIS contained both HPV18 and HPV16 DNA. High-risk human papillomavirus was not detected in any cases of LEGH or LEGH with AIS or GA.

P16 and CA-IX expression
------------------------

Carbonic anhydrase-IX immunoreactivity in the tissue sections was observed in 100% (12 out of 12) of CGLs and p16 in 92% (11 out of 12). With the exception of one poorly differentiated adenocarcinoma, the positive staining for both CA-IX and p16 was intense (2+ to 3+) and diffuse ([Figure 2B and C](#fig2){ref-type="fig"}). Carbonic anhydrase-IX expression was also seen in all 13 cases of LEGH with or without AIS or GA. Carbonic anhydrase-IX expression in those glands without typical features was limited to central larger glands ([Figure 1B](#fig1){ref-type="fig"}). In contrast, in those cases of LEGH with atypical features diffuse CA-IX immunoreactivity was seen, not only limited to the central larger glands but also in those glands with atypical cytological features ([Figure 3B and E](#fig3){ref-type="fig"}) and the glands with papillary configuration ([Figure 3H](#fig3){ref-type="fig"}). For those cases of AIS or GA with coexisting LEGH, all malignant glands exhibited diffuse strong CA-IX immunoreactivity ([Figure 2E](#fig2){ref-type="fig"}). In contrast, only 62% (8 out of 13) of LEGH, LEGHs with atypia and LEGHs with AIS or GA expressed p16, and the immunoreactivity in all cases was either negative ([Figure 2F](#fig2){ref-type="fig"}) or very weak cytoplasmic staining ([Figure 3C, F and I](#fig3){ref-type="fig"}). For the negative control group, CA-IX expression was either negative or limited to few reserve cells or columnar cells. Furthermore, the intensity of staining was weak and cytoplasmic ([Figure 2G](#fig2){ref-type="fig"}). These findings are consistent with our previous observation ([@bib12]). Carbonic anhydrase-IX expression was also tested on exfoliative cervical cells in PS from all cases of CGL, LEGH, LEGH with atypia and LEGH with coexisting AIS or GA. With the exception of one LEGH without atypia, diffuse strong immunopositive staining was seen in exfoliative endocervical glandular cells in all cases (data not shown and [Figure 2H and I](#fig2){ref-type="fig"}).

Discussion
==========

It is widely accepted that H-HPV infection has a crucial role in the aetiology of cervical carcinoma. Almost all cases of squamous cell carcinomas and the vast majority of adenocarcinomas were reported to contain H-HPV genotypes. However, in our recent study, conducted on Japanese women with a cytological diagnosis of AGC, H-HPV infection was identified in only 53% of cervical adenocarcinomas ([@bib17]). In this study, retrospective review of the histology found that 13 of 15 H-HPV-negative cases exhibited histological features of LEGH with or without the coexisting AIS or GA. When these special subsets of glandular lesions are excluded, the prevalence of H-HPV DNA detection in CGLs in this study was 83% (10 out of 12), which falls within the range of 83--100% reported in the literature ([@bib27]). In the case of the two H-HPV-negative AIS (see [Table 1](#tbl1){ref-type="table"}), one exhibited gastric morphology without associated destructive stromal reaction. This raises the possibility that this lesion may represent *in situ* GA, although this has not been definitively proven. Interestingly, this gastric-type like AIS was also p16 negative. The other HPV-negative case had histological features of conventional AIS, but the lesion in this case was limited to two glands. Thus, the negative result in this case may be due to insufficient H-HPV DNA load. Furthermore, this explanation is supported by the observation of diffuse expression of the p16 protein, a biomarker strongly correlated with H-HPV infection.

LEGH is a rare lesion of the uterine cervix that usually occurs in postmenopausal women, with a reported incidence of 0.7% ([@bib20]). In this study, we identified 13 out of 84 (15%) of LEGHs and, among these, 6 (46%) had coexisting AIS or GA. The rate of LEGH and LEGH associated with AIS or GA in our study is higher than that reported in the literature ([@bib20]; [@bib22]) and this discrepancy may be attributed to our focus on the selection of cases where only women with a cytological diagnosis of AGC were included. All 13 cases, and one AIS without associated LEGH, reported here exhibited gastric phenotype, which was further supported by positive immunostaining of the lesions with anti-MUC-6 antibody, a marker of pyloric glands (data not shown). None of these cases contained H-HPV DNA or expressed high levels of p16 protein. As illustrated in [Figure 3](#fig3){ref-type="fig"}, variable degrees of atypical features were observed in all LEGHs but one, and the expression of CA-IX protein appears to be closely related to the atypia. Our findings appear to support the notion that LEGH and GA are closely related lesions and arise independently of H-HPV infection. Similar H-HPV-negative cervical lesions have been recently reported that also exhibit special histological features described as LEGH, MDA, mucinous GA, mesonephric and clear-cell carcinoma. Thus, it is possible that separate and distinct molecular genetic events, independent of H-HPV infection, may have a role in the progression to the malignant condition in this category of cervical glandular lesions compared with CGLs.

Our previous studies have shown the diagnostic utility of CA-IX in detecting CGLs in patients with a cytological diagnosis of AGC. In this study, we show that practically all of the exfoliative endocervical glandular cells derived from the glandular cells of all cases of LEGH with atypia, AIS and adenocarcinoma of usual type or gastric phenotype showed diffuse and strong CA-IX immunoreactivity. Correspondingly, high levels of CA-IX expression were also identified in the tissue sections of all cases tested in the study. This novel finding has a significant clinical implication. It has been reported that most cases of GA, including MDA, are diagnosed at an advanced clinical stage and carry a poor prognosis ([@bib3]; [@bib9]). The vast majority of cases of GA was H-HPV negative and showed the absence or low levels of p16 expression. Thus, CA-IX protein expression in both exfoliative cells and tissue sections appears to serve as a useful biomarker for diagnosing LEGH-related lesions or the gastric phenotype neoplasms. Confirmation of this possibility awaits further analyses with more cases. Significant CA-IX expression in LEGHs with atypia and without associated carcinoma is an intriguing finding. Molecular genetic analyses of these cases should enable resolution of the speculation that LEGH may be a precursor of GA. Another area that warrants special consideration is the identification of the molecular genetic defects and aberrant signalling pathways that exist in this category of cervical glandular lesions as compared with the CGLs that are associated with H-HPV infection. High-risk human papillomavirus E6 and E7 products effectively abrogate the p53 and Rb tumour suppressor functions. Are these genes mutated in LEGH and/or GA cells or are other pathways operating that effectively bypass these powerful tumour suppressor functions?

In conclusion, our study has supported the following claims: (1) H-HPV DNA, p16 and CA-IX protein expression are useful biomarkers for detecting CGLs; (2) the subset of cervical lesions that encompasses LEGH with coexisting AIS or GA arise independently of H-HPV infection; (3) CA-IX may serve as the optimal surrogate biomarker for identifying this subset of cervical neoplasm with gastric phenotype; (4) the spectrum of histological changes seen in LEGH, LEGH with atypia and LEGH with AIS or GA suggests there is a possible link between LEGH and mucinous GA; and (5) the high rate (46%) of LEGHs associated with AIS and GA observed in this study warrants special attention being paid to identify LEGH with atypia in those women with an AGC cytological diagnosis.
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![Histology of LEGH, LEGH with atypia, LEGH with coexisting AIS and mucinous GA and CA-IX expression in LEGH. Lobular endocervical glandular hyperplasia without atypia (**A**) shows distinct lobular proliferation of the small- to medium-sized round glands surrounding larger central cystic dilated glands. The glands are lined by tall, mucin-rich columnar cells with a basal arrangement of nuclei, similar to pyloric glands (**A**, inset). Lobular endocervical glandular hyperplasia with atypia (**C**, **D**): some show nuclear enlargement, conspicuous nucleoli and apoptosis (**C**, arrow); some exhibit papillary growth with nuclear irregularity and loss of polarity (**D**). Adenocarcinoma *in situ* is defined as when the gland was replaced by cytologically malignant cells with associated apoptosis and/or mitosis (**E**). Adenocarcinoma with gastric phenotype exhibits voluminous clear cytoplasm with stromal desmoplastic reaction (**F**). Note the small invasive gland embedded in the desmoplastic stroma (**F**, arrow). Carbonic anhydrase-IX expression in the LEGH without atypia is limited to the central larger cystic glands (**B**, arrow). Original magnifications: × 100 in (**A**) and × 400 (**A**, inset and **B**--**F**).](bjc2012578f1){#fig1}

![**Examples of CA-IX and p16 immunoreactivity in CGL, GA and CA-IX expression in normal cervix and exfoliated endocervical cells**. Strong membranous reaction for CA-IX (**B**) and cytoplasmic and nuclear staining for p16 (**C**) was seen in all cases of CGL, but the normal gland was non-reactive for CA-IX or p16 (**B** and **C**, arrows). In contrast, in cases of GA only strongly positive CA-IX staining was seen (**E**), and p16 expression was either weakly cytoplasmic or negative (**F**). In normal cervical glands, CA-IX expression was limited to a few columnar/reserve cells, and the staining was weak and limited to the cytoplasm (**G**, arrow). Atypical glandular cells (**H**) derived from GA and normal looking glandular cells (**I**) derived from LEGH with atypia showed diffuse strong membranous positivity for CA-IX. The relevant haematoxylin and eosin (H&E)-stained tissue sections are shown in (**A**) and (**D**). Original magnifications: × 200 in (**D**--**F**) and × 400 in (**A**--**C**, **G**--**I**).](bjc2012578f2){#fig2}

![**Histology and immunohistochemical staining for CA-IX and p16 protein expression in LEGH with atypia**. In contrast to [Figure 1B](#fig1){ref-type="fig"}, CA-IX immunoreactivity was not only limited to the central larger glands but was also observed in the atypical glands (**B**, arrow, and **E**). Diffuse CA-IX membranous positivity was also seen in LEGH with atypical papillary growth (**H**). Note that the small glands without atypia were CA-IX negative (**E**, arrow). In contrast, p16 expression in all cases of LEGH with atypia was either negative or exhibited very weak cytoplasmic staining (**C**, **F**and **I**). The relevant haematoxylin and eosin (H&E)-stained tissue sections are shown in (**A**, **D** and **G**). Original magnification: × 400.](bjc2012578f3){#fig3}

###### Detection of the expression of CA-IX and p16 proteins and H-HPV DNA in CGLs

                                   **CA-IX**     **p16**     **H-HPV**
  -------------- ---------------- ------------ ----------- --------------
  **Case no.**    **Diagnosis**    **(100%)**   **(92%)**    **(83%)**
  1                    AIS           3+ (D)      3+ (D)       Negative
  2                    AIS           3+ (D)         0         Negative
  3                    AIS           3+ (D)      3+ (D)       Pos (16)
  4                    AIS           3+ (D)      3+ (D)       Pos (16)
  5                    AIS           3+ (D)      3+ (D)       Pos (18)
  6                    AIS           3+ (D)      3+ (D)       Pos (18)
  7                    AIS           3+ (D)      3+ (D)       Pos (18)
  8                    AIS           3+ (D)      3+ (D)     Pos (16; 18)
  9               Adenocarcinoma     3+ (D)      3+ (D)       Pos (18)
  10              Adenocarcinoma     3+ (D)      3+ (D)       Pos (18)
  11              Adenocarcinoma     3+ (D)      3+ (D)       Pos (18)
  12              Adenocarcinoma     3+ (F)      3+ (F)       Pos (18)

Abbreviations: AIS=adenocarcinoma *in situ*; CA-IX=carbonic anhydrase-IX; CGL=conventional glandular lesion; H-HPV=high-risk human papillomavirus; Neg=negative; Pos=positive; D=diffuse positive (⩾50% of cells); F=focal; (16;18)=HPV type.

###### Detection of expression of CA-IX and p16 proteins and H-HPV DNA in cases of LEGH, and well-differentiated mucinous GA

                      **CA-IX**   **p16**            **H-HPV**
  ---- ------------- ----------- --------- -------- -----------
  1        LEGH        2+ (F)       ---                None
  2     LEGH+atypia    2+ (D)       ---                None
  3     LEGH+atypia    3+ (D)               1+ (F)     None
  4     LEGH+atypia    3+ (F)               1+ (F)     None
  5     LEGH+atypia    2+ (F)       ---                None
  6     LEGH+atypia    3+ (D)               1+ (F)     None
  7     LEGH+atypia    2+ (D)               1+ (F)     None
  8      LEGH+AIS      3+ (D)       ---                None
  9      LEGH+AIS      3+ (D)               1+ (F)     None
  10     LEGH+AIS      2+ (F)       ---                None
  11      LEGH+GA      2+ (D)               1+ (F)     None
  12      LEGH+GA      3+ (D)               1+ (F)     None
  13      LEGH+GA      3+ (D)               1+ (F)     None

Abbreviations: AIS=adenocarcinoma *in situ*; CA-IX=carbonic anhydrase-IX; D=diffuse (positivity in ⩾50% of cells); F=focal; GA, adenocarcinoma with gastric phenotype; H-HPV=high-risk human papillomavirus; LEGH=lobular endocervical glandular hyperplasia.

The immunoreactivity of p16-positive cases was weak (1+) and focal. In contrast, CA-IX positivity was always intense (2+, 3+).
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